Agilent Technologies Inc (NYSE:A) has been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $79.00.
A has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on shares of Agilent Technologies from $84.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. Goldman Sachs Group reissued a “buy” rating and set a $82.00 target price (up from $77.00) on shares of Agilent Technologies in a research note on Tuesday, September 18th. ValuEngine raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, November 2nd. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Finally, Deutsche Bank boosted their price target on shares of Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, August 15th.
In other news, Director Heidi Fields sold 5,482 shares of the stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $67.73, for a total transaction of $371,295.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul N. Clark sold 2,876 shares of the stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $68.60, for a total transaction of $197,293.60. The disclosure for this sale can be found here.
Several institutional investors and hedge funds have recently added to or reduced their stakes in A. OppenheimerFunds Inc. raised its holdings in shares of Agilent Technologies by 64.0% during the second quarter. OppenheimerFunds Inc. now owns 7,636,621 shares of the medical research company’s stock worth $472,248,000 after acquiring an additional 2,980,216 shares during the period. American Century Companies Inc. increased its stake in Agilent Technologies by 16.9% in the 3rd quarter. American Century Companies Inc. now owns 5,359,933 shares of the medical research company’s stock valued at $378,090,000 after buying an additional 774,771 shares during the last quarter. Wells Fargo & Company MN increased its stake in Agilent Technologies by 6.6% in the 2nd quarter. Wells Fargo & Company MN now owns 2,984,214 shares of the medical research company’s stock valued at $184,544,000 after buying an additional 183,728 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Agilent Technologies by 3.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,329,409 shares of the medical research company’s stock valued at $82,211,000 after buying an additional 49,527 shares during the last quarter. Finally, Morgan Stanley increased its stake in Agilent Technologies by 67.6% in the 2nd quarter. Morgan Stanley now owns 1,227,627 shares of the medical research company’s stock valued at $75,917,000 after buying an additional 495,160 shares during the last quarter.
A stock traded down $0.52 during midday trading on Monday, reaching $67.27. The company had a trading volume of 2,573,534 shares, compared to its average volume of 2,758,899. The company has a quick ratio of 3.00, a current ratio of 3.62 and a debt-to-equity ratio of 0.39. Agilent Technologies has a fifty-two week low of $60.42 and a fifty-two week high of $75.00. The company has a market cap of $21.76 billion, a P/E ratio of 28.50, a PEG ratio of 2.13 and a beta of 1.35.
Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 14th. The medical research company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.04. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Agilent Technologies had a return on equity of 18.61% and a net margin of 6.20%. The firm’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.59 earnings per share. Analysts expect that Agilent Technologies will post 2.71 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 24th. Investors of record on Tuesday, October 2nd were issued a $0.149 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend was Monday, October 1st. Agilent Technologies’s dividend payout ratio is presently 25.42%.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.